Innovative Medicine
-
Johnson & Johnson Announces Start of Phase 1 Clinical Trial of Ebola Vaccine Regimen
Company Has Produced More Than 400,000 Vaccine Regimens for Use in Large-Scale Clinical Trials by April 2015 -
Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults -
Real-World Data Presented at the American Heart Association (AHA) Scientific Sessions Underscore Hospitalization and Outpatient Cost-Savings for XARELTO® Compared to Standard of Care
Findings Add to Existing Data Showing XARELTO® Cost-Savings Value Across Indications -
Johnson & Johnson Announces Completion Of Alios Biopharma Acquisition
Further Strengthens Existing Pipeline to Address Infectious Diseases -
-
Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting
Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4469, 4680 -
OLYSIO® (simeprevir) Gains Additional FDA Approval as Once-Daily, All-Oral Interferon- and Ribavirin-Free Treatment Option in Combination with Sofosbuvir for Adults with Genotype 1 Chronic Hepatitis C Infection
Expanded indication includes both treatment-naïve and treatment-experienced adult patients with or without cirrhosis -
-
Johnson & Johnson Announces Agreement To Acquire Alios BioPharma
Acquisition Strengthens Existing Pipeline in Viral Diseases